#2173244
Dá bhrí sin, is grúpa ARfD le haghaidh moirfín agus cóidín an ARfD, arna shloinneadh i gcoibhéisí moirfín.
The ARfD is therefore a group ARfD for morphine and codeine, expressed in morphine equivalents.
Filter results
Collections
25 results in 11 documents
#2122854
I gcás roinnt meastachán géarnochta, sáraíodh an ARfD i gcás roinnt grúpaí den daonra.
For several acute exposure estimates, the ARfD was exceeded for several population groups.
#2503503
I meastacháin áirithe ghéarnochta, sáraíodh an ARfD 1 μg/kg bw.
The ARfD of 1 μg/kg bw was exceeded in certain acute exposure estimates.
#2512284
géardháileog thagartha (ARfD) a leagan síos, i gcás inarb ábhartha, do dhaoine;
establish, where relevant, an acute reference dose (ARfD) for humans;
#307861
Beidh san áireamh sna sainchomhaid a thíolactar de bhun Airteagal 7(1) an fhaisnéis is gá chun an Iontógáil Laethúil Inghlactha (ADI), Leibhéal Inghlactha i dtaca leis an Oibreoir a bheith faoi lé na Substainte (AOEL) agus an Ghéardháileog Thagartha (ARfD) a shuíomh más ábhartha.
The dossiers submitted pursuant to Article 7(1) shall contain the information needed to establish, where relevant, Acceptable Daily Intake (ADI), Acceptable Operator Exposure Level (AOEL) and Acute Reference Dose (ARfD).
#307884
3.6.1. I gcás inarb ábhartha, déanfar ADI, AOEL agus ARfD bhunú.
3.6.1. Where relevant, an ADI, AOEL and ARfD shall be established.
#307950
- gurb ísle go suntasach a ADI, ARfD nó AOEL ná mar is amhlaidh i gcás thromlach na substaintí gníomhacha formheasta laistigh de ghrúpaí substaintí/catagóirí úsáide,
- its ADI, ARfD or AOEL is significantly lower than those of the majority of the approved active substances within groups of substances/use categories,
#2122847
Shocraigh an tÚdarás géardháileog thagartha ghrúpa (“ARfD”) arb é atá inti 0,016 μg/kg den mheáchan choirp (“b.w.”) arna sloinneadh mar shuim an (-)-hióisciaimín agus an (-)-scópolaimín, ag glacadh leis go bhfuil neart coibhéasach ann.
The Authority established a group acute reference dose (‘ARfD’) of 0.016 μg/kg per body weight (‘b.w.’) expressed as the sum of (-)-hyoscyamine and (-)-scopolamine, assuming equivalent potency.
#2122848
Bunaithe ar an eolas teoranta a bhí ar fáil, tháinig an tÚdarás ar an gconclúid gur féidir go sáródh nochtadh cothúcháin lapadán ARfD an ghrúpa a shárú go mór.
The Authority concluded that, based on the limited information available, the dietary exposure of toddlers could significantly exceed the group ARfD.
#2173245
Léirítear sna meastacháin nochta gur dóiche go sárófar an grúpa ARfD, go háirithe i gcás ina n-itear sciartha móra, nó má itear bia ina bhfuil síolta poipín neamhphróiseáilte.
Exposure estimates indicate that the group ARfD is likely to be exceeded, in particular, when large portions are consumed, or if foods containing unprocessed poppy seeds are consumed.
#2495139
Tháinig an tÚdarás ar an gconclúid nár cheart go mbeadh éifeachtaí díobhálacha géara ag nochtadh an duine faoi bhun na géardháileoige tagartha (ARfD) 20 μg ciainíd/kg meáchan coirp (bw).
The Authority concluded that a human exposure below the acute reference dose (ARfD) of 20 μg cyanide/kg body weight (bw) should not produce acute adverse effects.
#2495140
I gcás ina gcaitear bianna áirithe amhail rois, almóinní agus casabhach ina bhfuil leibhéil arda gliocóisídí cianaigineacha, d’fhéadfaí an ARfD le haghaidh ciainíde a shárú.
If certain foods such as linseed, almonds and cassava with high levels of cyanogenic glycosides are consumed, the ARfD for cyanide could be exceeded.
#2503500
Shocraigh an tÚdarás an ghéardháileog thagartha (ARfD) arb é atá inti 1 μg Δ9-THC/kg de mheáchan coirp (bw).
The Authority established an acute reference dose (ARfD) of 1 μg Δ9-THC/kg body weight (bw).
#2712683
Mhol an tÚdarás, ar bhonn na staidéar ar néarthocsaineacht fhorbarthach, gur cheart iontógáil laethúil inghlactha níos ísle (ADI) agus géardháileog thagartha (ARfD) níos ísle a leagan síos.
The Authority proposed, based on the developmental neurotoxicity studies, that a lower acceptable daily intake (ADI) and acute reference dose (ARfD) should be established.
#2743254
Thairis sin, tugadh le fios sa réamh-mheasúnú ar ghéar-riosca cothútháin i gcás tomhaltóirí gur sáraíodh go mór an ghéardháileog thagartha le haghaidh na n-úsáidí ionadaíocha uile maidir leis na barra inite uile.
Furthermore, the preliminary acute consumer dietary risk assessment indicated a large exceedance of the acute reference dose (‘ARfD‘) for all the representative uses on all edible crops.
#2173243
Dheimhnigh an tÚdarás an ghéardháileog thagartha (ARfD) ina bhfuil 10 μg moirfín/kg de mheáchan coirp (bw) agus chinn sé gur cheart tiúchan an chóidín sna samplaí de shíolta poipín a chur san áireamh trí chóidín a thiontú ina gcoibhéisí moirfín, trí úsáid a bhaint as fachtóir 0,2.
The Authority confirmed the acute reference dose (ARfD) of 10 μg morphine/kg body weight (bw) and concluded that the concentration of codeine in the poppy seed samples should be taken into account by converting codeine to morphine equivalents, using a factor of 0,2.
#2506633
I gcás meatocsaifeinisíde, i gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (“an tÚdarás”) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena ndeimhnítear an iontógáil laethúil inghlactha (ILI) atá ann cheana agus lena mbunaítear géardháileog thagartha níos ísle (ARfD).
For methoxyfenozide, in the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, confirming the existing acceptable daily intake (ADI) and establishing a lower acute reference dose (ARfD).
#2506634
I gcomhréir le hAirteagal 43 de Rialachán (CE) Uimh. 396/2005, d’iarr an Coimisiún ar an Údarás tuairim réasúnaithe a thabhairt, ina ndéanfaí measúnú ar na rioscaí a d’fhéadfadh a bheith ag baint leis na MRLanna atá ann faoi láthair do thomhaltóirí i ndáil le meatocsafeineaisíníd, i bhfianaise an ARfD níos ísle a luaitear thuas.
In accordance with Article 43 of Regulation (EC) No 396/2005, the Commission requested the Authority to provide a reasoned opinion, assessing the risks that the current MRLs for methoxyfenozide may pose to consumers, in light of the above-mentioned lower ARfD.
#2506646
I gcás spíonasad, i gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009, chuir an tÚdarás isteach conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear, den chéad uair, ARfD.
For spinosad, the Authority submitted, in the context of the procedure for the renewal of approval of that active substance in accordance with Regulation (EC) No 1107/2009, a conclusion on the peer review of the risk assessment of that active substance, establishing, for the first time, an ARfD.
#2506647
I gcomhréir le hAirteagal 43 de Rialachán (CE) Uimh. 396/2005, d’iarr an Coimisiún ar an Údarás measúnú a dhéanamh ar na rioscaí do thomhaltóirí a d’fhéadfadh a bheith ag baint leis na MRLanna le haghaidh spíonasad atá ann cheana i bhfianaise an ARfD nua sin.
In accordance with Article 43 of Regulation (EC) No 396/2005, the Commission requested the Authority to assess the risks that the current MRLs for spinosad may pose to consumers in the light of that new ARfD.
#2712684
An 3 Feabhra 2021, agus i gcomhréir le hAirteagal 43 de Rialachán (CE) Uimh. 396/2005, d’iarr an Coimisiún ar an Údarás tuairim réasúnaithe a sholáthar ina ndéanfaí measúnú ar na rioscaí a bhféadfadh baint a bheith acu le MRLanna áirithe atá ann faoi láthair le haghaidh abaimeictine, i bhfianaise an ADI agus an ARfD níos ísle a luaitear thuas.
On 3 February 2021 and in accordance with Article 43 of Regulation (EC) No 396/2005, the Commission requested the Authority to provide a reasoned opinion assessing the risks on certain existing MRLs for abamectin that may pose to consumers in light of the lower ADI and ARfD.
#3206736
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (ILI) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (ADI) and a lower acute reference dose (ARfD).
#3206737
I gcomhréir le hAirteagal 43 de Rialachán (CE) Uimh. 396/2005, d’iarr an Coimisiún ar an Údarás tuairim réasúnaithe a thabhairt, ina ndéanfaí measúnú ar na rioscaí a d’fhéadfadh a bheith ag baint leis na MRLanna atá ann faoi láthair, lena n-áirítear iad siúd atá bunaithe ar uasteorainneacha iarmhar Codex (CXLanna), i gcás ocsaimile, i gcás tomhaltóirí i bhfianaise an laghdaithe ar an ILI agus ar an ARfD sin.
In accordance with Article 43 of Regulation (EC) No 396/2005, the Commission requested the Authority to provide a reasoned opinion, assessing the risks that the current MRLs, including those based on Codex maximum residue limits (CXLs), for oxamyl, may pose to consumers in light of those lower ADI and ARfD.
#3211004
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí iondocsacarb a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (‘ADI’) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of indoxacarb in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (‘ADI’) and a lower acute reference dose (‘ARfD’).
#3211007
I gcomhréir le hAirteagal 43 de Rialachán (CE) Uimh. 396/2005, d’iarr an Coimisiún ar an Údarás tuairim réasúnaithe a sholáthar maidir leis na rioscaí a bhféadfadh baint a bheith acu leis na MRLanna atá ann faoi láthair le haghaidh iondocsacarb atá bunaithe ar lamháltais allmhairiúcháin agus ar uasteorainneacha iarmhar Codex (‘CXLanna’) i bhfianaise an ADI agus an ARfD níos ísle.
In accordance with Article 43 of Regulation (EC) No 396/2005, the Commission requested the Authority to provide a reasoned opinion on the risks that the current MRLs for indoxacarb based on import tolerances and Codex maximum residue limits (‘CXLs’) may pose to consumers in light of the lower ADI and ARfD.